The results demonstrated that pathways associated with tumor progressions, such as glycolysis, the G2/M checkpoint, Myc targets, PI3K-AKT-mTOR, DNA repair, hypoxia, and epithelial-mesenchymal transition, were mainly enriched in the high-risk group of LUAD patients. This evidence concerns the gene AKT1 and neoplasm.